Elsewhere in this Drug Review Profile, the Pink Sheet examines how the US Food and Drug Administration took the Omicron variant's predominance into account in its review and January approval of Moderna, Inc.'s COVID-19 vaccine Spikevax.(Also see "COVID-19 Vaccines: Spikevax Review Reflected Changing Realities Of Omicron In US" - Pink Sheet, 4 May, 2022.)
US FDA's Spikevax Review By The Numbers
A timeline of the development and approval of Moderna's mRNA vaccine, and a listing of FDA reviewers on the biologics license application.
